Edition:
United States

Midatech Pharma PLC (MTP.OQ)

MTP.OQ on NASDAQ Stock Exchange Capital Market

1.01USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,470
52-wk High
$3.18
52-wk Low
$0.84

Chart for

About

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110

* APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110

Jan 16 2018

BRIEF-Midatech Pharma Enters Into Four-Year Senior Secured Loan Agreement With Midcap Financial Of Up To $15 Mln​

* MIDATECH PHARMA PLC - ‍HAS ENTERED INTO A FOUR-YEAR SENIOR SECURED LOAN AGREEMENT WITH MIDCAP FINANCIAL OF UP TO $15 MILLION​ Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-Midatech Pharma U.S. Initiates Gelclair Phase IV Trial To Study Oral Mucositis In Stem Cell Transplant Patients

* MIDATECH PHARMA US INITIATES GELCLAIR® PHASE IV TRIAL TO STUDY ORAL MUCOSITIS IN STEM CELL TRANSPLANT PATIENTS

Dec 20 2017

BRIEF-Midatech Pharma announces proposed placing and open offer

* PROPOSED PLACING TO RAISE UP TO APPROXIMATELY £6 MILLION AND OPEN OFFER TO RAISE UP TO £2 MILLION

Sep 28 2017

Earnings vs. Estimates

No consensus analysis data available.